Utama › Leukemia Mieloid Akut › Kansas › Overland Park
Kajian klinikal Leukemia Mieloid Akut di Overland Park, KS
11 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi dalam dan sekitar Overland Park (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Mengambil pesertaFasa 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Mengambil pesertaFasa 3
- US-Kansas City KS-KUMC, Fairway · 3 mi jauh
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Mengambil pesertaFasa 1
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Mengambil pesertaFasa 1
- The University of Kansas Medical Center Research Institute, Fairway · 3 mi jauh
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Mengambil pesertaFasa 1
- University of Kansas, Fairway · 3 mi jauh
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Mengambil pesertaFasa 2
- University of Kansas Cancer Center, Fairway · 3 mi jauh
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Mengambil pesertaFasa 1
- University of Kansas Cancer Center, Fairway · 3 mi jauh
Kajian Leukemia Mieloid Akut di bandar lain
- Houston, TX85 kajian
- New York City, NY51 kajian
- Boston, MA44 kajian
- Seattle, WA41 kajian
- Baldwin Park, CA40 kajian
- Columbus, OH35 kajian
- Philadelphia, PA34 kajian
- Durham, NC33 kajian
- Atlanta, GA31 kajian
- Tampa, FL29 kajian
- Chicago, IL26 kajian
- Portland, OR25 kajian
Kajian lain di Overland Park
- Kanser Paru-paru Bukan Sel Kecil16 kajian
- Kanser Paru-paru11 kajian
- Kanser Payudara10 kajian
- Fibrilasi Atrium8 kajian
- Kanser Kolorektal8 kajian
- Obesiti7 kajian
- Kanser Pankreas7 kajian
- Kanser Prostat7 kajian
- Melanoma6 kajian
- Berat Badan Berlebihan6 kajian
- Kanser Ovari6 kajian
- Kanser (semua jenis)5 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.